4d Molecular Therapeutics (NASDAQ: FDMT)
$5.84
(-8.2%)
-$0.52
Price as of January 8, 2025, 4:00 p.m. ET
4d Molecular Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
4d Molecular Therapeutics Company Info
4D Molecular Therapeutics, Inc. operates as a clinical stage biotherapeutics company, which engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. It offers products for ophthalmology, cardiology, and pulmonology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.